Login to Your Account


Synageva Biopharma’s $211.5M public offering raises the bar for 2014 follow-ons

By Marie Powers
Staff Writer

Thursday, March 6, 2014
Synageva Biopharma Corp. priced the largest underwritten public offering for a biotech so far in 2014, seeking to raise $211.5 million and leaving no doubt that the public markets continue to lavish capital on the rare disease space.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription